The dramatic changes taking place in many aspects of the medical device industry, from new materials to new business models, are coming together in certain product areas, providing a glimpse of the future device world. One such example is abdominal aortic aneurysm (AAA) surgery, which, having remained virtually unchanged for nearly 40 years, is on the verge of a major transformation, resulting in AAA becoming an important business opportunity. Large device companies are making early investments, trying to pick start-up winners, while emerging companies hope there are some partners left, even though no products are yet available in the US.
by Stephen Levin
For years the medical device industry has been roiling with change at all levels—discoveries in biomaterials and other building blocks...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”
While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
